NASDAQ:VYGR Voyager Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.18 -0.24 (-3.74%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$6.06▼$6.7550-Day Range$4.82▼$8.5252-Week Range$2.46▼$10.60Volume372,609 shsAverage Volume595,883 shsMarket Capitalization$237.66 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Voyager Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside21.4% Upside$7.50 Price TargetShort InterestHealthy3.62% of Float Sold ShortDividend StrengthN/ASustainability-0.38Upright™ Environmental ScoreNews Sentiment0.35Based on 4 Articles This WeekInsider TradingAcquiring Shares$2.66 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.71) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.24 out of 5 starsMedical Sector243rd out of 1,426 stocksBiological Products, Except Diagnostic Industry33rd out of 218 stocks 2.3 Analyst's Opinion Consensus RatingVoyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Voyager Therapeutics has a forecasted upside of 21.4% from its current price of $6.18.Amount of Analyst CoverageVoyager Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.62% of the float of Voyager Therapeutics has been sold short.Short Interest Ratio / Days to CoverVoyager Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Voyager Therapeutics has recently decreased by 24.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVoyager Therapeutics does not currently pay a dividend.Dividend GrowthVoyager Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVoyager Therapeutics has received a 76.52% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Voyager Therapeutics is -0.38. Previous Next 3.0 News and Social Media Coverage News SentimentVoyager Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Voyager Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows3 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Voyager Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,663,552.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders25.40% of the stock of Voyager Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.16% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Voyager Therapeutics is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Voyager Therapeutics is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVoyager Therapeutics has a P/B Ratio of 2.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VYGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Voyager Therapeutics (NASDAQ:VYGR) StockVoyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.Read More VYGR Stock News HeadlinesJuly 6, 2022 | nypost.comDallas Mavericks fans fume at Mark Cuban over Voyager crypto bankruptcyJuly 1, 2022 | msn.comCrypto firm Voyager suspends trading, deposits and withdrawalsJune 24, 2022 | msn.comVoyager Craft Coffee now brewing in CupertinoJune 24, 2022 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Major Shareholder Ecor1 Capital, Llc Purchases 101,400 Shares of StockJune 24, 2022 | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Major Shareholder Ecor1 Capital, Llc Buys 376,000 Shares of StockJune 24, 2022 | msn.comBitcoin billionaire Sam Bankman-Fried bails out embattled crypto firms BlockFi and VoyagerJune 23, 2022 | msn.comNASA’s Voyager probes are reaching the end of their livesJune 22, 2022 | msn.comTroubled Crypto Brokerage Voyager Presses Three Arrows Capital To Repay $650 Million Loan Amid Capital CrunchJune 22, 2022 | msn.comNASA prepares to shut down Voyager probe instruments after 44 yearsJune 21, 2022 | businessinsider.comNASA is starting to shut down the Voyager probes, which launched in 1977 and made it deeper into space than anything sinceJune 16, 2022 | americanbankingnews.comVoyager Therapeutics (NASDAQ:VYGR) Share Price Crosses Below Fifty Day Moving Average of $6.87June 13, 2022 | msn.comStar Trek: Voyager Gets Filmation-Style Animation [Video]June 10, 2022 | seekingalpha.comLooking Back In On Voyager TherapeuticsJune 9, 2022 | finance.yahoo.comInvestors in Voyager Therapeutics (NASDAQ:VYGR) have unfortunately lost 76% over the last three yearsMay 26, 2022 | za.investing.comWhat The Voyager Space Probes Can Teach Humanity About ImmortalityMay 25, 2022 | forbes.comCorsair’s Maiden Voyager Gaming Laptop Features Innovative Touch Bar And 240Hz DisplayMay 20, 2022 | msn.comNASA's Voyager 1 is sending mysterious data from beyond our solar system. Scientists are unsure what it means.May 19, 2022 | tmcnet.comVoyager Therapeutics' TRACER™ Capsids Demonstrate Enhanced CNSMay 19, 2022 | finance.yahoo.comVoyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy ProgramsMay 16, 2022 | tmcnet.comVoyager Therapeutics to Present Preclinical Data from itsMay 16, 2022 | finance.yahoo.comVoyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual MeetingMay 4, 2022 | seekingalpha.comVoyager Therapeutics GAAP EPS of -$0.56, revenue of $0.7M misses by $12.01MMay 4, 2022 | finance.yahoo.comVoyager Therapeutics Reports First Quarter 2022 Financial and Operating ResultsMay 3, 2022 | finance.yahoo.comVoyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual MeetingApril 25, 2022 | finance.yahoo.comWhat Kind Of Shareholders Own Voyager Therapeutics, Inc. (NASDAQ:VYGR)?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VYGR CUSIPN/A CIK1640266 Webwww.voyagertherapeutics.com Phone(857) 259-5340FaxN/AEmployees101Year FoundedN/ACompany Calendar Last Earnings5/04/2022Today7/06/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$9.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+21.4%Consensus RatingModerate Buy Rating Score (0-4)2.66666666666667 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,200,000.00 Net Margins-224.48% Pretax Margin-224.48% Return on Equity-76.83% Return on Assets-34.93% Debt Debt-to-Equity RatioN/A Current Ratio1.68 Quick Ratio1.68 Sales & Book Value Annual Sales$37.42 million Price / Sales6.35 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book2.47Miscellaneous Outstanding Shares38,456,000Free Float28,688,000Market Cap$237.66 million OptionableOptionable Beta1.06 Voyager Therapeutics Frequently Asked Questions Should I buy or sell Voyager Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Voyager Therapeutics stock. View analyst ratings for Voyager Therapeutics or view top-rated stocks. What is Voyager Therapeutics' stock price forecast for 2022? 3 analysts have issued 1 year target prices for Voyager Therapeutics' stock. Their VYGR stock forecasts range from $6.00 to $9.00. On average, they expect Voyager Therapeutics' stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View analysts' price targets for Voyager Therapeutics or view top-rated stocks among Wall Street analysts. How has Voyager Therapeutics' stock price performed in 2022? Voyager Therapeutics' stock was trading at $2.71 at the beginning of 2022. Since then, VYGR shares have increased by 128.0% and is now trading at $6.18. View the best growth stocks for 2022 here. When is Voyager Therapeutics' next earnings date? Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Voyager Therapeutics. How were Voyager Therapeutics' earnings last quarter? Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.42. The firm earned $0.66 million during the quarter, compared to analyst estimates of $28.25 million. Voyager Therapeutics had a negative trailing twelve-month return on equity of 76.83% and a negative net margin of 224.48%. View Voyager Therapeutics' earnings history. Who are Voyager Therapeutics' key executives? Voyager Therapeutics' management team includes the following people: Mr. Robert W. Hesslein, Sr. VP & Gen. Counsel (Age 69, Pay $576.62k)Mr. G. Andre Turenne, Advisor (Age 48, Pay $600.3k)Dr. Alfred W. Sandrock Jr., M.D., Ph.D., Pres, CEO & Director (Age 64)Dr. Krystof Bankiewicz M.D., Ph.D., FounderDr. Guangping Gao Ph.D., FounderDr. Mark A. Kay M.D., Ph.D., Founder (Age 64)Dr. Phillip D. Zamore, FounderMs. Julie Burek, VP of Fin. (Age 47) (LinkedIn Profile)Ms. Robin Swartz, Chief Operating Officer (Age 51)Ms. Michelle Quinn Smith, Chief HR Officer Who are some of Voyager Therapeutics' key competitors? Some companies that are related to Voyager Therapeutics include Anavex Life Sciences (AVXL), Arcellx (ACLX), Atara Biotherapeutics (ATRA), iTeos Therapeutics (ITOS), Instil Bio (TIL), Coherus BioSciences (CHRS), Agenus (AGEN), Sangamo Therapeutics (SGMO), NanoString Technologies (NSTG), Osiris Therapeutics (OSIR), Inhibrx (INBX), Cullinan Oncology (CGEM), Immatics (IMTX), Century Therapeutics (IPSC) and Ocugen (OCGN). View all of VYGR's competitors. What other stocks do shareholders of Voyager Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT). What is Voyager Therapeutics' stock symbol? Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR." How do I buy shares of Voyager Therapeutics? Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Voyager Therapeutics' stock price today? One share of VYGR stock can currently be purchased for approximately $6.18. How much money does Voyager Therapeutics make? Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $237.66 million and generates $37.42 million in revenue each year. The company earns $-71,200,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. How many employees does Voyager Therapeutics have? Voyager Therapeutics employs 101 workers across the globe. How can I contact Voyager Therapeutics? Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for Voyager Therapeutics is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com. This page (NASDAQ:VYGR) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
